St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world's deadliest childhood cancers. The team has joined forces to decode the genomes of more than 600 childhood cancer patients treated at St. Jude, who have contributed tumour samples for this historic effort.
The St. Jude Children's Research Hospital - Washington University Paediatric Cancer Genome Project is the largest investment to date-estimated to cost $65 million over three years-aimed at understanding the genetic origins of childhood cancers. Scientists involved in the project will sequence the entire genomes of normal and cancer cells from each patient, comparing differences in the DNA to identify genetic mistakes that lead to cancer. Kay Jewelers, a long-standing supporter of St. Jude Children's Research Hospital, has committed to providing $20 million as lead sponsor of this project.
"We are on the threshold of a revolution in our understanding of the origins of cancer. For the first time in history, we have the tools to identify all of the genetic abnormalities that turn a white blood cell into a leukaemia cell or a brain cell into a brain tumour," said Dr. William E. Evans, St. Jude director and chief executive officer. "We believe it is from this foundation that advances for 21st century cancer diagnosis and treatment will come."
St. Jude is home to one of the world's largest and most complete repositories of biological information about childhood cancer. The collection dates to the 1970s and includes more than 50 000 tumour, bone marrow, blood and other biological samples. These samples are essential to efforts to understand the origins of cancer. The tissue bank has also helped St. Jude scientists develop the experimental models expected to be important for determining which mutations drive cancer's development and spread.
The collaboration focuses on childhood leukaemia's, brain tumours and tumours of bone, muscle and other connective tissues called sarcomas. St. Jude will provide DNA from tumour and normal tissues of patients, Washington University's Genome Centre will perform the whole genome sequencing, and both will participate in validation sequencing. Researchers at both institutions will collaborate to analyze the data and make the information publicly available once validated. Prior research by this group and others indicates that the many genetic abnormalities in childhood cancers will differ from those found in adult cancers.
"This extraordinary partnership will add a new dimension to our understanding of childhood cancers," says paediatric geneticist Dr. Larry J. Shapiro, executive vice chancellor and dean of Washington University School of Medicine. "A genome-wide understanding of cancer offers great promise for developing powerful new approaches to diagnose and treat cancer or perhaps even to prevent it. In the short term, the project will yield key genetic information that may ultimately help physicians choose the best treatment options for young cancer patients."
Scientists at Washington University's Genome Centre pioneered whole-genome sequencing of cancer patients' genomes. In 2008, they became the first to decode the complete genome of a cancer patient - a woman with leukaemia - and trace her disease to its genetic roots. They have since sequenced the genomes of additional cancer patients, including those with breast, lung and ovarian tumours and glioblastoma, a type of brain tumour. These studies have identified intriguing and unexpected genetic connections between patients with different types of cancer that likely would not have been discovered using conventional approaches.
Earlier research to identify cancer mutations has typically focused only on the few hundred genes already suspected of being involved in the disease. While a few recent studies have involved sequencing the 20 000 or so protein-coding genes in the genome, the whole-genome approach involved in this collaboration provides a more detailed and complete picture of all the mutations involved in a patient's cancer by examining both the protein-coding genes and the long stretches of DNA between genes, which may influence the ways the genes work. Such complete genomic sequencing is now possible because of recent advances that have made the technology faster and far less expensive.
Researchers involved in the project also will investigate how paediatric cancer is influenced by variations in the genome, including epigenetic changes, which alter the expression of genes but not the genes themselves. They also will use DNA sequencing data to identify genetic markers that can help physicians decide the best treatment options for cancer patients, based on the genetic profile of their tumours.
The project's scope and design reflects the philosophies and talents of the institutions involved. St. Jude and Washington University have a history of scientific collaboration and a track record of innovation in patient care. They also share a commitment to excellence and openness in research. The paediatric genome project will include a public database where information, once validated, will be shared with the international scientific community, with the goal of accelerating progress against childhood cancer.
While great progress has been made in treating childhood cancer, it is still the leading cause of death from disease among U.S. children over one year of age, and cure rates for some childhood cancers remain below 50%.
Source: St. Jude Children's Research Hospital
